Literature DB >> 9856409

Polysystic ovary syndrome--loss of the apoptotic mechanism in the ovarian follicles?

R Homburg1, A Amsterdam.   

Abstract

Polycystic ovary syndrome (PCOS) is the most prevalent female endocrinopathy and the largest single cause of anovulatory infertility. The PCOS is characterized by multiple small antral follicles arrested in their development but nonatretic and viable. The hyperexpression of some growth factors (e.g. EGF/TGF alpha) in PCOS, considered to be survival or antiapoptotic factors, led to the hypothesis of their involvement in the blocking of apoptosis and atresia leading to an accumulation of multiple small antral follicles. Diminished FSH stimulation and accumulation of androgens could explain the arrest of progress to the preovulatory stage. Further investigation of the pathogenesis of PCOS is needed on the modulation of tumour suppressor and apoptosis genes such as p53, BAX or the APO/FAS system and the over expression of survival genes such as BCL2.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9856409     DOI: 10.1007/bf03350780

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  38 in total

Review 1.  Control of differentiation, transformation, and apoptosis in granulosa cells by oncogenes, oncoviruses, and tumor suppressor genes.

Authors:  A Amsterdam; N Selvaraj
Journal:  Endocr Rev       Date:  1997-08       Impact factor: 19.871

Review 2.  Ovarian follicle atresia: a hormonally controlled apoptotic process.

Authors:  A J Hsueh; H Billig; A Tsafriri
Journal:  Endocr Rev       Date:  1994-12       Impact factor: 19.871

3.  Induction of Mdm2 and enhancement of cell survival by bFGF.

Authors:  E Shaulian; D Resnitzky; O Shifman; G Blandino; A Amsterdam; A Yayon; M Oren
Journal:  Oncogene       Date:  1997-11-27       Impact factor: 9.867

4.  Multifollicular ovaries: clinical and endocrine features and response to pulsatile gonadotropin releasing hormone.

Authors:  J Adams; S Franks; D W Polson; H D Mason; N Abdulwahid; M Tucker; D V Morris; J Price; H S Jacobs
Journal:  Lancet       Date:  1985 Dec 21-28       Impact factor: 79.321

5.  Follicular fluid steroid and epidermal growth factor content, and in vitro estrogen release by granulosa-luteal cells from patients with polycystic ovaries in an IVF/ET program.

Authors:  A Volpe; G Coukos; G D'Ambrogio; P G Artini; A R Genazzani
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  1991-12-13       Impact factor: 2.435

6.  Overexpression of a human transforming growth factor-alpha (TGF alpha) transgene reveals a dual antagonistic role of TGF alpha in female sexual development.

Authors:  Y J Ma; G A Dissen; G Merlino; A Coquelin; S R Ojeda
Journal:  Endocrinology       Date:  1994-10       Impact factor: 4.736

7.  Apoptosis during luteal regression in cattle.

Authors:  J L Juengel; H A Garverick; A L Johnson; R S Youngquist; M F Smith
Journal:  Endocrinology       Date:  1993-01       Impact factor: 4.736

8.  Production of transforming growth factor-alpha by normal and polycystic ovaries.

Authors:  H D Mason; L Carr; R Leake; S Franks
Journal:  J Clin Endocrinol Metab       Date:  1995-07       Impact factor: 5.958

9.  Involvement of p53 expression in cAMP-mediated apoptosis in immortalized granulosa cells.

Authors:  I Keren-Tal; B S Suh; A Dantes; S Lindner; M Oren; A Amsterdam
Journal:  Exp Cell Res       Date:  1995-05       Impact factor: 3.905

Review 10.  Morphology and morphogenesis of the Stein-Leventhal ovary and of so-called "hyperthecosis".

Authors:  P E Hughesdon
Journal:  Obstet Gynecol Surv       Date:  1982-02       Impact factor: 2.347

View more
  8 in total

Review 1.  Ovarian and Extra-Ovarian Mediators in the Development of Polycystic Ovary Syndrome.

Authors:  Muraly Puttabyatappa; Vasantha Padmanabhan
Journal:  J Mol Endocrinol       Date:  2018-10-16       Impact factor: 5.098

2.  Tumor-induced osteomalacia characterized by "painful knee joint with difficulty in moving": a case report.

Authors:  Lan Jiang; Qing-Qing Tan; Chen-Lin Gao; Ling Xu; Jian-Hua Zhu; Pi-Jun Yan; Ying Miao; Qin Wan; Yong Xu
Journal:  BMC Endocr Disord       Date:  2022-07-08       Impact factor: 3.263

3.  Developmental programming: differential effects of prenatal testosterone and dihydrotestosterone on follicular recruitment, depletion of follicular reserve, and ovarian morphology in sheep.

Authors:  Peter Smith; Teresa L Steckler; Almudena Veiga-Lopez; Vasantha Padmanabhan
Journal:  Biol Reprod       Date:  2008-12-17       Impact factor: 4.285

4.  Developmental programming: Impact of prenatal testosterone treatment and postnatal obesity on ovarian follicular dynamics.

Authors:  V Padmanabhan; P Smith; A Veiga-Lopez
Journal:  J Dev Orig Health Dis       Date:  2012-08       Impact factor: 2.401

5.  Proprotein convertase furin regulates apoptosis and proliferation of granulosa cells in the rat ovary.

Authors:  Xiaokui Yang; Qingxin Wang; Zhiying Gao; Zhi Zhou; Sha Peng; Wen-Lin Chang; Hai-Yan Lin; Weiyuan Zhang; Hongmei Wang
Journal:  PLoS One       Date:  2013-02-13       Impact factor: 3.240

6.  Serum 25-Hydroxyvitamin D Levels, phosphoprotein enriched in diabetes gene product (PED/PEA-15) and leptin-to-adiponectin ratio in women with PCOS.

Authors:  Silvia Savastano; Rossella Valentino; Carolina Di Somma; Francesco Orio; Claudia Pivonello; Federica Passaretti; Valentina Brancato; Pietro Formisano; Annamaria Colao; Francesco Beguinot; Giovanni Tarantino
Journal:  Nutr Metab (Lond)       Date:  2011-11-23       Impact factor: 4.169

7.  The local effects of ovarian diathermy in an ovine model of polycystic ovary syndrome.

Authors:  Fiona Connolly; Michael T Rae; Mairead Butler; Alexander L Klibanov; Vassilis Sboros; Alan S McNeilly; W Colin Duncan
Journal:  PLoS One       Date:  2014-10-24       Impact factor: 3.240

8.  Ultrasound Characterization of Disordered Antral Follicle Development in Women with Polycystic Ovary Syndrome.

Authors:  Brittany Y Jarrett; Heidi Vanden Brink; Alexis L Oldfield; Marla E Lujan
Journal:  J Clin Endocrinol Metab       Date:  2020-11-01       Impact factor: 5.958

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.